ANTX
AN2 Therapeutics Inc
5.10$
+3.1%
vs. previous close
Closing price · As of: Sep 18, 2026
Statements
Cash Flow
AN2 Therapeutics Inc (ANTX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -30 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| -2.5 | -5.4 | -20 | -33 | -53 | -49 | -30 | |
| – | – | – | -0.7 | – | – | – | |
| – | 0.0 | 1.0 | 4.4 | 8.4 | 8.3 | 6.2 | |
| 19 | 7.0 | 1.0 | 3.8 | – | – | – | |
| 0.0 | 1.2 | 0.0 | 3.7 | 5.8 | -3.0 | 0.2 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| -50 | -50 | -50 | -22 | -43 | 55 | 28 | |
| – | – | – | 1.8 | – | – | – | |
| – | – | – | 0.0 | – | – | – | |
| 8.1 | 3.8 | 79 | 70 | 85 | 0.4 | 0.1 | |
| 5.6 | -1.5 | 8.0 | 15 | -12 | 5.7 | -1.4 | |
| -2.5 | -5.4 | -20 | -33 | -53 | -49 | -30 |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.